{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:23:19Z","timestamp":1788967399405,"version":"build-2803163510"},"reference-count":47,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"\n Importance<\/jats:title>\n Interleukin (IL)-17 inhibitors have emerged as effective therapies for moderate to severe hidradenitis suppurativa (HS), but concerns remain regarding their potential association with inflammatory bowel disease (IBD). It is known that there is an increased risk of IBD in HS populations, but it remains unclear whether IL-17 inhibition increases the IBD risk or unmasks underlying disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the incidence of IBD in patients with HS treated with IL-17 inhibitors and to compare IBD event rates between treatment and placebo groups.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Embase, and the Cochrane CENTRAL were searched from inception through November 2025.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Randomized clinical trials (RCTs), nonrandomized studies, and case reports reporting IBD outcomes in patients with HS treated with IL-17 inhibitors were included. Of 1467 records identified, 24 studies met inclusion criteria (10 RCTs, 11 nonrandomized studies, and 3 case reports).<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Extracted variables included study design, IL-17 inhibitor, study duration, dosing regimen, sample size, patient age, sex, baseline personal or family history of IBD, new-onset IBD, relapse of preexisting IBD, IBD subtype and clinical features, and time to IBD onset.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incidence of IBD event, defined as new-onset or worsening Crohn disease or ulcerative colitis during IL-17 inhibitor treatment in a patient with HS. For RCTs, pooled risk differences were calculated using a common effects Mantel-Haenszel model. For nonrandomized studies, a single group meta-analysis of proportions was performed to estimate pooled IBD incidence. Case reports were synthesized qualitatively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Across 10 RCTs, new-onset IBD occurred in 6 of 2572 patients treated with IL-17 inhibitors (0.23%) and in 0 of 1066 patients treated with placebo through week 16. There was no significant difference between groups (risk difference, 0.002; 95% CI, \u22120.003 to 0.007). In nonrandomized studies, 7 new-onset IBD events occurred among 469 patients (crude incidence, 1.49%), with a pooled incidence of 3.90% (95% CI, 2.30%-6.50%). Across randomized trials, long-term extension studies, and nonrandomized studies, 17 new-onset cases and 4 IBD flares were reported.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this systematic review and meta-analysis, IBD events were rare. No significant increase in IBD risk was observed with IL-17 inhibitors, although low event rates and inconsistent reporting limited interpretation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.3373","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:42Z","timestamp":1788966042000},"source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa"],"prefix":"10.1001","author":[{"given":"Marley","family":"Cutrona","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana L.","family":"Jolkovsky","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Romanelli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"O\u2019Hagan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Susan & Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"5","key":"doi260041r1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi260041r2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa.","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi260041r3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","article-title":"Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States.","volume":"68","author":"Cosmatos","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"doi260041r4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions.","volume":"35","author":"Jemec","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi260041r5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study.","volume":"133","author":"Canoui-Poitrine","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"10443","key":"doi260041r6","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"doi260041r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103818","article-title":"The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials.","volume":"24","author":"Heidari","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"10378","key":"doi260041r8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10476","key":"doi260041r10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa.","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"doi260041r11","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial.","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"11","key":"doi260041r12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease.","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"doi260041r13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis.","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"doi260041r14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in vigibase.","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"doi260041r15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2024.2343112","article-title":"An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.","volume":"24","author":"Stergianou","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"doi260041r16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation.","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"issue":"5","key":"doi260041r17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jid.2016.11.040","article-title":"Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa.","volume":"137","author":"Egeberg","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7","key":"doi260041r18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jamadermatol.2018.0878","article-title":"Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States.","volume":"154","author":"Garg","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"71","key":"doi260041r19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"doi260041r20","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool.","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"11","key":"doi260041r21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial.","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi260041r27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jaad.2025.11.031","article-title":"Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.","volume":"94","author":"Sayed","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi260041r28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/bjd\/ljae469","article-title":"Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.","volume":"192","author":"Kimball","year":"2025","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi260041r31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ajd.14267","article-title":"Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice.","volume":"65","author":"Osorio-G\u00f3mez","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"3","key":"doi260041r32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260041r33","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial.","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi260041r34","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1111\/jdv.16605","article-title":"Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases).","volume":"34","author":"Reguia\u00ef","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi260041r35","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting.","volume":"35","author":"Ribero","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi260041r36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.piel.2024.02.001","article-title":"Efectividad y seguridad de los f\u00e1rmacos biol\u00f3gicos y las mol\u00e9culas peque\u00f1as en la hidradenitis supurativa: experiencia en un centro terciario y propuesta de un algoritmo terap\u00e9utico.","volume":"39","author":"Mansilla-Polo","year":"2024","journal-title":"Piel"},{"issue":"11","key":"doi260041r37","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s13555-025-01521-z","article-title":"Long-term effectiveness and safety of bimekizumab in patients with moderate to severe hidradenitis suppurativa under real clinical practice conditions: the importance of combined treatment in Hurley III patients and potential factors associated with complete response.","volume":"15","author":"Mansilla-Polo","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"doi260041r38","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.5826\/dpc.1501a4915","article-title":"Secukinumab treatment in patients with hidradenitis suppurativa in real-world clinical settings: a multicenter study.","volume":"15","author":"Erbagci","year":"2025","journal-title":"Dermatol Pract Concept"},{"issue":"7","key":"doi260041r39","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","article-title":"Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study.","volume":"14","author":"Haselgruber","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"doi260041r40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study.","volume":"17","author":"Martora","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"doi260041r41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2512156","article-title":"Potential clinical factors associated with secukinumab dose selection in the treatment of hidradenitis suppurativa: a cohort study of 132 patients.","volume":"36","author":"Soto Moreno","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"doi260041r42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00464-023-10072-3","article-title":"Acute intussusception cause by suspected secukinumab-induced inflammatory bowel disease.","volume":"37","author":"Altom","year":"2023","journal-title":"Surg Endosc"},{"issue":"10S","key":"doi260041r43","doi-asserted-by":"publisher","first-page":"S1713","DOI":"10.14309\/01.ajg.0000959400.96782.31","article-title":"Secukinumab induced colitis masquerading as IBD.","volume":"118","author":"Niazi","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"S1","key":"doi260041r44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.16406","article-title":"Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports.","volume":"179","author":"Cotter","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi260041r45","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40744-021-00360-6","article-title":"Systematic review and meta-analysis of inflammatory bowel disease adverse events with anti-interleukin 17a agents and tumor necrosis factor inhibitors in rheumatic disease and skin psoriasis.","volume":"8","author":"Truong","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"5","key":"doi260041r46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis.","volume":"15","author":"Burisch","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"doi260041r47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"doi260041r9","unstructured":"MoonLake Immunotherapeutics. MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab. Updated September 28, 2025. Accessed August 4, 2026. https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-reports-week-16-results-vela-phase-3"},{"key":"doi260041r22","unstructured":"MoonLake Immunotherapeutics. Evaluation of Sonelokimab for the Treatment of Patients with Active Moderate to Severe Hidradenitis Suppurativa (MIRA). Updated May 3, 2024. Accessed June 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05322473"},{"key":"doi260041r23","unstructured":"MoonLake Immunotherapeutics. A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (VELA-1). Updated June 8, 2026. Accessed June 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06411899"},{"key":"doi260041r24","unstructured":"MoonLake Immunotherapeutics. Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (VELA-2). Updated June 8, 2026. Accessed June 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06411379"},{"key":"doi260041r25","unstructured":"Acelyrin Inc. Hidradenitis Suppurativa Phase 2B Study of Izokibep. Updated June 3, 2025. Accessed June 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05355805"},{"key":"doi260041r26","unstructured":"Acelyrin Inc. Hidradenitis Suppurativa Study of Izokibep. Updated October 15, 2025. Accessed June 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05905783"},{"key":"doi260041r29","unstructured":"Brunk? D. Novel agent shows promise for hidradenitis suppurativa. Accessed June 30, 2026. https:\/\/www.mdedge.com\/internalmedicine\/article\/268365\/medical-dermatology\/novel-agent-shows-promise-hidradenitis\/page\/0\/1"},{"key":"doi260041r30","doi-asserted-by":"crossref","unstructured":"Papp? K, Bechara? FG, Porter? ML, . Efficacy of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: week 32 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study. Presented at: American Academy of Dermatology; March 2026; Denver, Colorado. Accessed August 6, 2026. https:\/\/eposters.aad.org\/archives\/AM2026\/71352","DOI":"10.1016\/j.jaad.2026.04.781"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853488\/jamadermatology_cutrona_2026_oi_260041_1787587988.12827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:47Z","timestamp":1788966047000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853488"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3373","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}